TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Korean Post-marketing Surveillance for Xeljanz

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in the study all patients will have received at least 1 dose of Xeljanz for the treatment of the following indication as per local labelling. Moderately to severely active RA in adult patients who have had an inadequate response or intolerance to previous therapy with at least 1 biological DMARD. Or Active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to previous antirheumatic drugs (DMARDs)~Exclusion Criteria:~1. Patients with a history of hypersensitivity to any ingredients of the product.~2. Patients with serious infection (eg, sepsis) or active infection including localized infection.~3. Patients with active tuberculosis.~4. Patients with severe hepatic function disorder.~5. Patients with an absolute neutrophil count (ANC) \<500 cells/mm3.~6. Patients with a lymphocyte count \<500 cells/mm3.~7. Patients with a hemoglobin concentration \<8 g/dL.~8. Pregnant or possibly pregnant women.~9. Because of lactose contained in this drug, it should not be administered to patients with hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.~According to Contraindication on label, the investigator should discontinue the patient's treatment if the laboratory test results are as below Patients with an absolute neutrophil count (ANC) \<500 cells/mm3 Patients with a hemoglobin level \<8 g/dL

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy, male Caucasians between 18 and 45 years of age.~* Normotensive subjects (systolic BP \< 140 mmHg and diastolic BP \<90 mmHg;~* Body weight of 70 to 90 kg (BMI 20 - 25.~* Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests;~* Signed Informed Consent Form.~* Normal coagulation function (aPTT between 24 and 35 seconds, PT between 70 and 130%, INR between 0.85 and 1.15.~Exclusion Criteria:~* Subjects who are taking or have taken any prescription medication within the last 14 days or any non-prescription medication, especially, anti-platelet drugs, within the last seven days prior to the administration of trial medication on Day 1.~* Intake of any investigational drug within three months prior to the administration of study medication on Day 1.~* Concomitant use of any other medication including over-the-counter preparations.~* History of hypersensitivity, contraindication or serious adverse reaction to inhibitors of platelet aggregation or hypersensitivity to related drugs (cross-allergy) or to any of the excipients in the study drug.~* A history or clinical evidence of any cardiac, cardio- or cerebrovascular, hepatic, renal, pulmonary, endocrine, neurological, infectious, gastrointestinal, haematological, oncological or psychiatric disease or emotional problems or any other clinically relevant condition, physical finding, ECG- or laboratory test abnormality, which - in the opinion of the investigator - would pose a significant risk for the subject, invalidate the Informed Consent or limit the ability of the subject to comply with study requirements or interfere otherwise with the conduct of the study.~* Any laboratory value outside the normal laboratory reference range at Screening and before randomization, unless approved by the investigator.~* Subjects known to have experienced elevated liver enzyme values will also be excluded.~* History of alcohol and/or drug abuse (verified by drug screening).~* Blood loss of 450 ml or more during the last three months before Screening.~* Subjects who smoke more than 5 cigarettes per day and/or are unable to abstain from smoking during the entire in-house period.~* Subjects who were previously enrolled in this trial or who have received PR-15 in a previous trial.~* Subjects who have participated in other clinical trials in the last 3 months.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Methylprednisolone in Endovascular Aortic Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective endovascular repair of an asymptomatic abdominal aortic aneurysm.~* Informed signed consent~Exclusion Criteria:~* Positive HIV status, positive hepatitis B or C status~* Immunoinflammatory disease - except topically treated skin disease and respiratory disease.~* Glaucoma~* Gastric or duodenal ulcer~* Systemic fungal infection~* Immunosuppressive treatment~* Current treatment for cancer~* Allergy towards contents of Solu-Medrol~* Alcohol consumption: Men \> 21 drinks and women \> 14 drinks weekly~* Pregnancy~* Lack of informed signed consent~* Patients where follow up is planned at other location than Rigshospitalet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone (Type: ACTIVE_COMPARATOR): 75 patients will receive a single preoperative dosage of Methylprednisolone
- Physiological Saline (Type: PLACEBO_COMPARATOR): 75 patients will receive a single preoperative dosage of Physiological Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Receiving oral antihyperglycemic medications (including metformin) without insulin injection in the last 90 days~* Hemoglobin A1c (HbA1c) equal to or greater than 7.0% but less than 11.0%~* Willing to receive insulin injection while continuing to take the prestudy oral antihyperglycemic medications~* Able to perform self monitoring of blood glucose~Exclusion Criteria:~* Are taking any other glucose-lowering agents other than metformin, sulfonylurea or Thiazolidinedione (Pioglitazone)~* Have taken acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide in the past 6 weeks, or for a total of 30 days or more, in the last 24 weeks~* Have a body mass index greater than 35 kg/m2~* History or presence of kidney disease~* Have cardiac disease (Class III or IV)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Insulin lispro low mixture (Type: EXPERIMENTAL): Insulin lispro low mixture (1, 2 or 3 daily injections)
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Antibiotic Treatment of Erythema Migrans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* solitary erythema migrans in patients \> 15 years~Exclusion Criteria:~* a history of Lyme borreliosis in the past~* pregnancy or lactation~* immunocompromised status~* serious adverse event to doxycycline~* taking antibiotic with antiborrelial activity within 10 days~* multiple erythema migrans or extracutaneous manifestations of Lyme borreliosis

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- EM-10 days doxycycline (Type: ACTIVE_COMPARATOR): None
- EM-doxycycline 15 days (Type: ACTIVE_COMPARATOR): None
- controls (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented skin disease classical for chronic GvHD (e.g. hypopigmentation, hyperpigmentation, lichenoid lesions, sclerodermatous lesions)greater than or equal to 100 days post transplantation.~* Patients with documented chronic GvHD that is corticosteroid refractory, corticosteroid dependent or corticosteroid intolerant.~* Women of childbearing potential must agree to use a reliable method of birth control for the duration of this study.~* Patients must weight at least 40 kg (88 lbs.)~Exclusion Criteria:~* Active gastrointestinal bleeding~* Previous treatment with ECP~* Females who are pregnant and/or lactating

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Participant is scheduled to undergo elective colon or colorectal surgery by~laparotomy that is scheduled in advance with adequate time prior to surgery to~complete preoperative bowel preparation.~- Participant is a Chinese adult between the ages of more than 18 years old and~less than 81 years old.~- Participant is highly unlikely to conceive.~Exclusion Criteria:~* Participant is undergoing emergency colon or colorectal surgery.~* Participant requires a second planned colorectal surgery or other surgery requiring antibiotic prophylaxis within the 4-week follow-up period.~* Participant is undergoing laparoscopic-assisted surgery.~* Participant is undergoing an isolated rectal procedure.~* Participant has a decompensated intestinal obstruction.~* Participant has active inflammatory bowel disease involving the colon (i.e.,~ulcerative colitis or Crohn's disease).~* Participant is scheduled to undergo an elective colorectal procedure for revision of a previous operation involving a large bowel resection.~* Participant has a bacterial infection at the time of surgery.~* Participant requires or is anticipated to need the administration of other (nonstudy therapy) systemic antimicrobial therapy within 1 week prior to surgery or at any time during this study.~* Participant is anticipated to receive either antibiotic or antiseptic peritoneal lavage during the surgery.~* Participant has a history of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to ertapenem sodium, ceftriaxone sodium, metronidazole, penicillin, or any cephalosporin, beta(β)-lactam, or nitroimidazole agents.~* Participant is breast feeding or plans to breast feed prior to the completion of the study period.~* Participant has neutropenia.~* Participant with immunosuppression due to an underlying disease, chronic~immunosuppressive therapy, or use of high-dose corticosteroids.~* Participant has a rapidly progressive or terminal illness.~* Participant is considered unlikely to survive through the expected 4-week study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ertapenem sodium 1 g (Type: EXPERIMENTAL): Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
- Ceftriaxone sodium 2 g (Type: ACTIVE_COMPARATOR): Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of B-cell chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, including Waldenstrom's macroglobulinemia, as indicated by the following:~  * Massive or progressive splenomegaly and/or lymphadenopathy~ * Anemia (hemoglobin less than 11 g/dL) or thrombocytopenia (platelet count less than 100,000/mm\^3)~ * Weight loss of more than 10% within the past 6 months~ * Grade 2 or 3 fatigue~ * Fevers greater than 100.5º C or night sweats for more than 2 weeks with no evidence of infection~ * Progressive lymphocytosis with an increase of more than 50% over a 2-month period or anticipated doubling time of less than 6 months~* Received at least 1 prior therapy for CLL~* Performance status - ECOG (Eastern Cooperative Oncology Group) 0-2~* See Disease Characteristics~* WBC (white blood count) less than 200,000/mm\^3~* Bilirubin no greater than 1.5 times normal (unless due to Gilbert's disease or any of the conditions stated below)\*~* AST (aspartate aminotransferase) no greater than 2 times normal\*~* Creatinine no greater than 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy that would limit survival to less than 2 years~* No history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) unless inactive for more than 2 years~* No psychiatric condition that would preclude compliance with treatment or giving informed consent~* No other concurrent chemotherapy~* No concurrent chronic corticosteroids~* No concurrent hormonal therapy except steroids for new adrenal failure or hormonal agents for nondisease-related conditions (e.g., insulin for diabetes)~* No concurrent dexamethasone or other corticosteroid-based antiemetics~* No concurrent radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants wtih birth weights from 401-1,000g~* Receiving mechanical ventilation or supplemental oxygen at 24-96 hours of age~Exclusion Criteria:~* Major congenital anomalies~* Congenital nonbacterial infection~* Infants diagnosed with a terminal illness (as indicated by a pH below 6.80 or by the presence of hypoxia with bradycardia for more than two hours)~* Infants who were to receive vitamin A in a parenteral fat emulsion or in doses exceeding recommendations for multivitamin preparations

- Gender: ALL
- Minimum Age: 24 Hours
- Maximum Age: 96 Hours
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Vitamin A group.
- Control (Type: SHAM_COMPARATOR): Sham procedure Control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. FOR TREATMENT-NAIVE GROUP ONLY: Men and women ≥ 65 years of age with confirmed diagnosis of CLL/SLL, who require treatment per NCI or International Working Group guidelines 15-18~2. FOR RELAPSED/REFRACTORY GROUP ONLY: Men and women ≥ 18 years of age with a confirmed diagnosis of relapsed/refractory CLL/SLL following previous therapy(ie, failed ≥ 2 previous treatments for CLL/SLL and at least 1 regimen had to have had a purine analog \[eg, fludarabine\] for subjects with CLL)~3. FOR HIGH-RISK RELAPSED/ REFRACTORYGROUP ONLY: Men and women ≥ 18 years of age with a confirmed diagnosis of relapsed/refractory CLL/SLL with suboptimal response to chemoimmunotherapy, defined as progression of disease within 24 months of initiation of a regimen containing at least a nucleoside analogue or bendamustine in combination with a monoclonal antibody or failure to respond to such a regimen. (Note: a minimum of 2 cycles of chemoimmunotherapy required for eligibility)~4. ECOG performance status of ≤ 2~5. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty~Exclusion Criteria:~1. Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for at least 2 years or which will not limit survival to \< 2 years~2. Any immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 4 weeks before first dose of study drug (corticosteroids for disease-related symptoms allowed but require 1-week washout before study drug administration)~3. Central nervous system (CNS) involvement by lymphoma~4. Major surgery within 4 weeks before first dose of study drug~5. Concomitant use of medicines known to cause QT prolongation or torsades de pointes~6. Significant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree AV block type II, 3rd degree block, bradycardia, and QTc \> 470 msec~7. Lactating or pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI-32765 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Major depressive disorder (DSM-IV)~2. Depression of moderate to severe degree (17+ on the 17-item Hamilton Depression Scale (HAM-D)).~3. No Magnetic Resonance Imaging (MRI) contraindications~4. No SSRI contraindications~5. Has a general practitioner (GP) or other mental healthcare professional who can confirm diagnosis~6. 18-80 years of age~7. Males and females~8. Sufficiently competent with English language~Key exclusion criteria:~1. Current or previously diagnosed psychotic disorder~2. Immediate family member with a diagnosed psychotic disorder~3. Medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure e.g. creatine clearance:renal clearance (CLRC) \< 30 ml/min etc.)~4. History of serious suicide attempts requiring hospitalisation.~5. Significant history of mania (determined by study psychiatrist and medical records)~6. Psychiatric condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin, e.g. borderline personality disorder~7. Blood or needle phobia~8. Positive pregnancy test at screening or during the study, women who are planning a pregnancy and/or women who are nursing/breastfeeding.~9. Participants who do not agree to use an acceptable contraceptive method throughout their participation in study.~10. Current drug or alcohol dependence~11. No email access~12. Use of contraindicated medication~13. Patients presenting with abnormal QT interval prolongation at screening or with a history of this (QTc at screening above 440ms for men and above 470ms for women)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Patients receive Psilocybin
- Escitalopram (Type: ACTIVE_COMPARATOR): Patients receive Escitalopram

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C \> 70 mg/dL and TG \< 400 mg/dL,~* Treated with a stable statin therapy; Atorvastatin 20/40 or Simvastatin 10/20~Exclusion Criteria:~* BMI \> or =35 kg/m2~* Significant cardiovascular disease~* HbA1c \> 10%~* Uncontrolled hypertension~* Active muscle disease~* GFR \< 60 ml/min~* Hepatic dysfunction~* Anemia~* Existing CETP deficiency~* History of Homozygous Familial Hypercholerstrolemia~* History of malignancy~* Alcohol abuse~* Treatment with investigational product~* Treatment with PCSK9~* Clinically significant condition~* Known CETP inhibitor allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Once-daily placebo
- 2.5 mg Obicetrapib (Type: EXPERIMENTAL): once-daily Obicetrapib
- 5 mg Obicetrapib (Type: EXPERIMENTAL): once-daily Obicetrapib
- 10 mg Obicetrapib (Type: EXPERIMENTAL): once-daily Obicetrapib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete